Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Rises By 5.1%

Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Free Report) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 644,000 shares, a growth of 5.1% from the January 15th total of 612,700 shares. Currently, 10.9% of the company’s shares are short sold. Based on an average daily trading volume, of 33,700 shares, the days-to-cover ratio is currently 19.1 days.

Greenwich LifeSciences Stock Up 1.0 %

NASDAQ:GLSI opened at $12.51 on Wednesday. Greenwich LifeSciences has a 1-year low of $10.52 and a 1-year high of $21.44. The firm’s 50-day moving average price is $12.56 and its 200-day moving average price is $13.43.

Insider Activity at Greenwich LifeSciences

In other news, CEO Snehal Patel acquired 3,200 shares of the business’s stock in a transaction on Monday, December 30th. The shares were acquired at an average cost of $11.12 per share, with a total value of $35,584.00. Following the transaction, the chief executive officer now owns 5,539,302 shares in the company, valued at $61,597,038.24. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have purchased 10,500 shares of company stock worth $128,459 over the last 90 days. 51.67% of the stock is owned by company insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its position in shares of Greenwich LifeSciences by 54.8% in the 4th quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock worth $32,000 after purchasing an additional 1,008 shares in the last quarter. Brown Brothers Harriman & Co. bought a new stake in Greenwich LifeSciences in the fourth quarter worth $45,000. JPMorgan Chase & Co. boosted its holdings in Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after acquiring an additional 4,465 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after acquiring an additional 1,322 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.

Read Our Latest Research Report on GLSI

Greenwich LifeSciences Company Profile

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Featured Articles

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.